Peptide Tools to Study Cancer

In almost any organ, tumors can develop and the cancerous cells often spread within the body through the blood or the lymphatic system to form metastases. Among the most common cancers are: 

  • Prostate cancer
  • Breast cancer
  • Lung cancer
  • Colon cancer
  • Skin cancer (melanoma)

Tumor Antigens & Peptides

Tumor associated antigens are expressed by tumor cells and can be recognized by the host's immune system either by immune cells or by antibodies. Although tumor antigens are larger proteins, the detected T-cell epitopes are short peptides. In contrast, antibody epitopes can be linear, represented by relatively short peptide stretches, or they depend on a certain protein conformation that requires longer peptide sequences for proper interaction. 

Effector            Peptide Length Presentation Peptide pool
CD8+ cytotoxic T cells  8 - 10 aa MHC I Peptide Pools
Peptide Libraries
CD4+ T cells 12 - 18 aa MHC II Peptide Pools
Peptide Libraries
Antibodies  small peptide epitopes  MHC independent Peptide Microarrays
Peptide ELISA


Peptide Products & Services for Cancer Research:

Clinical Peptides

JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.

Cellular Immune Response Profiling

JPT offers tailored custom peptides, peptide libraries and peptide pools for HCMV research. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your research project.

 
  • Immune monitoring
  • Immunotherapy
  • Epitope discovery
  • Ready-made peptide pools for TAAs such as Erb/Her2 and MAGE and for tumor viruses such as HPV
  • Custom PepMix™ peptide pools
  • Vaccine development
  • High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Clinical trials
Individual peptides tailored to your needs. Flexible amount, purity, analysis and modification such phosphorylation, biotinlyation, fluorescence labels etc.

Humoral Immune Response Profiling

JPT is the technology leader for peptide microarrays. We offer a range of pre-made catalog peptide microarrays for multiple TAAs and production of customized peptide microarrays. In addition, we provide a modular assay and analysis service using high content peptide microarrays, multiwell microarrays and peptide ELISA.

  • Immune monitoring of humoral response
  • Profiling of cancer specific samples or antibodies
  • Detection of epitopes and epitope spreading
  • Vaccine target identification
  • Catalog Peptide Microarray for TAAs such as Erb/Her2 and Survivin and for tumor viruses
  • Tailored PepStar™ Peptide Microarrays: you define content and layout
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.

Cancer & Epigenetics

Histones
Histones are part of nucleosomes that build up the chromatin in eukaryotic cells. Histone proteins undergo a variety of post-translational modifications (PTMs e.g. methylation, acetylation, phosphorylation, citrullination). Combinations of these modifications regulate histone interaction with the DNA and other proteins, thus affecting diverse biological processes such as gene regulation, DNA repair, mitosis and meiosis. Abnormal histone modification patterns have been associated with a large number of human malignancies.
The Histone Code Peptide Microarray contains more than 3800 histone peptides with and without PTMs. All potential combinations of post-translational modifications are represented. JPT’s comprehensive Histone Code Microarray enables mapping of protein-histone interactions with unprecedented resolution.
Acetylation of lysine residues in proteins and peptides is a posttranslational modification (PTM) that plays a major role in regulating transcription and other metabolic processes. We created two high-density peptide microarrays, each displaying 5599 peptides derived from reported human non-histone acetylation targets.

Cancer Proteomics

Identification of biomarkers and profiling of protein expression signatures can be used to develop and improve anti-cancer therapies, diagnostics and to enhance our understanding of carcinogenesis and signaling pathways.

 
Proteotypic Peptide Sets & Pools (SpikeTides™ Sets & SpikeMixes™)
JPT produced sets of proteotypic peptides for the detection and relative quantification of the most relevant tumor associated antigens (TAA) and human cytokines using SRM/MRM assays.
The ready-to-use proteotypic peptide sets and pools are available in two specifications, containing either light or heavy isotope labeled peptides (C-terminal Arg U-13C6; U-15N4 or Lys U-13C6; U-15N2) and is delivered in three 96 well plates.

Tailored Proteotypic Peptides - SpikeTides™
SpikeTides™ are tailored proteotypic peptides, delivered individually or pooled. The proteotypic peptides are synthesized with heavy isotope labeled or light arginine or lysine. For absolute quantification JPT developed a proprietary JPT-tag. The tagged proteotypic peptides enable a cost efficient and more reliable absolute quantification of peptide standards for proteome wide profiling using SRM/MRM proteomic assays.

Loading...

References

References

Selected Cancer Related References

  • Use of MS-GUIDE for identifcation of protein biomarkers for risk stratifcation of patients with prostate cancer
    Goetze et al., Clinical Proteomics (2022) - PMID : 35477343
  • Transcriptome profling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line
    Vasiliou et al., Clinical Proteomics (2022)
  • Diagnosing pleural efusions using mass spectrometry‑based multiplexed targeted proteomics quantitating mid‑to high‑abundance markers of cancer, infection/infammation and tuberculosis
    Robak et al., Scientific Reports (2022) 

  • Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
    Weber et al., Nature Biotechnology (2022)
  • CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
    Jin et al., Nature Biomedicical Engineering (2022)
  • CD206+ tumor-associated macrophages cross-present tumor antigen and drive anti-tumor immunity
    Modak et al., JCI Insight (2022) - PMID: 35503656
    Products used: Antigen Peptide NY-ESO-1 - HLA-A*0201 (SLLMWITQC)
  • Linear DNA amplicons as a novel cancer vaccine strategy
    Conforti et al., BioRxiv (2022)
  • Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers
    Jenny Dunn et al., Cancers (2022) - PMID: 35326747
  • Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
    Matsuzaki et al., Oncoimmunology (2022) - PMID: 35003898
    Products used: PepMix™ Human (Claudin-6)
  • The human CXCR3 chemokine system in early differentiated CD8+ T cell function and solid tumors
    Tino Vollmer, Dissertation (2022)
  • New Monoclonal Antibodies That Recognize an Unglycosylated, Conserved, Extracellular Region of CD44 in Vitro and in Vivo, and Can Block Tumorigenesis
    Daniel F. Lusche et al., PLOS ONE (2021) - PMID: 33891595
  • Identification of Potential Salivary Biomarker Panels for Oral Squamous Cell Carcinoma
    Anu Jain et al., Sci Rep, (2021)
  • Transcriptional Programs of Neoantigen-Specific TIL in Anti-PD-1-Treated Lung Cancers
    Caushi, J.X. et al., Nature, (2021)
  • Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
    Bassel Akache et al., Pharmaceutics, (2021)
  • Reversion Analysis Reveals the in Vivo Immunogenicity of a Poorly MHC I-Binding Cancer Neoepitope
    Hakimeh Ebrahimi-Nik et al., Nat Commun, (2021)
  • Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology
    Natalia Sacilotto et al., ACS Pharmacol Trans Sci, (2021)
  • Dysfunction of Exocytosis Causes Catecholamine Hypersecretion in Patient With Pheochromocytoma
    Sébastien Houy et al., BioRxiv, (2021)
  • Screening for New Peptide Substrates For the Development of Albumin Binding Anticancer Pro-Drugs That Are Cleaved By Prostate-Specific Antigen (PSA) to Improve The Anti Tumor Efficacy
    Bakheet E.M. et al., Biochemistry and Biophysics Reports (2021) - PMID: 33718631
  • Proteomic Analysis of Urinary and Tissue‐Exudative Extracellular Vesicles to Discover Novel Bladder Cancer Biomarkers
    Eisuke Tomiyama et al., Cancer Sci, (2021)
  • Profiling the HCV Immune Response in Patients With Chronic Liver Diseases and Hepatocellular Carcinoma by Peptide Microarray Analysis
    Anna Lucia Tornesello et al., Curr Med Chem, (2021)
  • NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
    Atsushi Takatori et al., Front Oncol, (2021)
  • Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
    Adam S Kibel et al., J Natl Cancer Inst. (2021) - PMID: 33630063
  • Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
    Anna Przybyla et al., Cancers (Basel) (2021) - PMID: 33435427
  • Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
    Maja Stanojevic et al., Cytotherapy, (2021)
  • Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple Myeloma
    Nandakumar Packiriswamy et al., Leukemia (2020) - PMID: 32327728
  • Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI)
    Leah S. Price et al., Journal of Quantitative Cell Science (2020) - PMID: 33090656
  • Microwave Ablation Enhances Tumor‑Specific Immune Response In Patients With Hepatocellular Carcinoma
    Katharina Leuchte et al., Cancer Immunology, Immunotherapy (2020) - PMID: 33006650
  • Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics Analysis
    Chuan Zhang et al., Diagnostics (2020) - PMID: 31991631
  • An Unbiased Approach to Defining Bona Fide Cancer Neoepitopes That Elicit Immune-Mediated Cancer Rejection
    Cory A. Brennick et al., J Clin Invest. (2020) - PMID: 33320837
  • Identification of two HLA-A*0201 Immunogenic Epitopes of Lactate Dehydrogenase C (LDHC): Potential Novel Targets for Cancer Immunotherapy
    Remy Thomas et al., Cancer Immunology, Immunotherapy (2020) - PMID: 31932876
  • Modified Natural Killer Cells And Natural Killer Cells Lines Targeting Tumour Cells
    Michael Eamon Peter O'dwyer et al., United States Patent Application 20200392458 (2020) - PMID: n.a.
  • Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma
    Dr. Biagio De Angelis et al., Immunology And Immunopathology (2020) - PMID: 29615432
  • In Vitro Comparison of the Effects ofImatinib and Ponatinib on ChronicMyeloid Leukemia Progenitor/Stem CellFeatures
    Ignazia Tusa et al., Targeted Oncology (2020) - PMID: 32780298
  • Globally Altered Epigenetic Landscape and Delayed Osteogenic Differentiation in H3.3-G34W-Mutant Giant Cell Tumor of Bone
    Pavlo Lutsik et al., Nature (2020) - PMID: 33110075
  • An HER2 DNA Vaccine with Evolution-Selected Amino Acid Substitutions Reveals a Fundamental Principle for Cancer Vaccine Formulation in HER2 Transgenic Mice
    Jones et al, Cancer Immunology, Immunotherapy (2019)
  • Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans
    Anna Przybyla et al, Cancer Immunology, Immunotherapy (2019)
  • Proteome-Wide Onco-Proteogenomic Somatic Variant Identification in ER-Positive Breast Cancer
    Dimitrakopoulos et al, Clinical Biochemistry (2019)
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational Study
    Crosby et al, Clinical Cancer Research (2019)
  • Rapalog Combined with CCR4 Antagonist Improves Anticancer Vaccines Efficacy
    Beziaud et al, International Journal of Cancer (2018)
  • CD11c+ MHCIIlo GM-CSF-Bone Marrow-Derived Dendritic Cells act as Antigen Donor Cells and as Antigen Presenting Cells in Neoepitope-Elicited Tumor Immunity Against a Mouse Fibrosarcoma
    Ebrahimi-Nik et al, Cancer Immunol Immunotherapy (2018)
  • Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine Lymphoma
    Impellizeri et al, Journal of Translational Medicine (2018)
  • An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung-Cancer Pleural Effusions
    Perzanowsk et al., Proteomics Clin Appl. (2018) - PMID: 29352525

Testimonials

Testimonials

 "Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized PepMix™ Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency."
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines. Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service. JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations."
Benedetto Farsaci, National Cancer Institute, NIH, Bethesda, MD, USA

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

Application Notes
Loading...

Check our list of products, click and go.

Get a quote